REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
35 hedge funds and large institutions have $2.13M invested in REVIVA PHARMA HLDGS INC in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 23 closing their positions.
4,527% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $30K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
44.89% more ownership
Funds ownership: 0.49% → 45.38% (+45%)
27% less funds holding
Funds holding: 48 → 35 (-13)
33% less capital invested
Capital invested by funds: $3.18M → $2.13M (-$1.05M)
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$3.47M |
| 2 |
Millennium Management
New York
|
+$3.1M |
| 3 |
AC
Armistice Capital
New York
|
+$2.69M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.19M |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$250K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$155K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$155K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$57.8K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$45.8K |
RVPH Hedge Fund Activity: Q1 2026 in Review
35 of the 8,169 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q1 2026, worth a combined $2.13M — down 33% from $3.18M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RVPH and 13 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $3.47M. The largest seller was Jane Street, exiting entirely with an estimated $250K sold.
- 35 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q1 2026, down from 48 in Q4 2025.
- Funds reported $2.13M of REVIVA PHARMA HLDGS INC stock for Q1 2026, down 33% quarter-over-quarter.
- 13 funds opened new REVIVA PHARMA HLDGS INC positions in Q1 2026 and 23 closed out, a net change of -10 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q1 2026 was Highbridge Capital Management, an estimated $3.47M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q1 2026 was Jane Street, an estimated $250K sold.
Based on aggregated 13F filings for Q1 2026.